Analysis of the various schemes efficiency of methotrexate use in psoriasis treatment
Year: 2017, volume 13 Issue: №3 Pages: 662-668
Heading: Dermatovenerology Article type: Original article
Authors: Kruglova L.S., Ponich E.S., Osina A.V., Griazeva N.V.
Organization: BU Khanty-Mansi Autonomous District— Yugra «Khanty-Mansi clinical skin and venereologic dispensary», Central State Medical Academy of the ADP of the Russian Federation
Heading: Dermatovenerology Article type: Original article
Authors: Kruglova L.S., Ponich E.S., Osina A.V., Griazeva N.V.
Organization: BU Khanty-Mansi Autonomous District— Yugra «Khanty-Mansi clinical skin and venereologic dispensary», Central State Medical Academy of the ADP of the Russian Federation
Summary:
Currently, there has been a steady increase in the incidence of psoriasis, including severe forms. It is extremely important for psoriasis to administrate medicines in time. Methotrexate inhibits the increased proliferation of keratinocytes, inhibits the production of such inflammatory mediators as leukotrienes, TNF-a, collagenase, IL-1, IL-6, but at the same time it increases production of anti-inflammatory IL-10. Objective: to analyze the efficacy of methotrexate in various forms of psoriasis. Material and Methods. Under observation in the period from 2011 to 2016 were 516 patients, including those treated with methotrexate. Methotrexate was assigned according to the scheme: 1st injection 10mg/week, with no adverse effects 20-25 mg/week. All patients received folic acid at a dose of 20-40 mg/day for 5 days starting 3 days after the injection of methotrexate. Evaluation of efficiency was carried out using indices of dermatological status and quality of life. Results. Achievement of clinical remission was observed in 257 (49.7%) in patients; achieving a significant improvement was noted in 32 (6.2%) patients; achieving improvements in 126 (24.4%) patients; no effect 33 (6.4%) patients, and deterioration (further progression of skin lesions) were observed in 68 (13.2%) patients. Conclusion. Methotrexate has a high efficacy in such clinical forms of psoriasis as vulgar (64.9%), inverse (63.9%), exudative (44.7%), and pustular palmar-plantar psoriasis 12.9%.
Bibliography:
1. KubanovaAA, KubanovAA, Nikolas JF, etal. Immune mechanisms of psoriasis: New strategies of biotherapy. Vestnik der-matologii I venerologii 2010; 1: 35-47
2. Potekaev NN, Kruglova LS. Psoriaticheskaya bolezn. Moscow: MDV, 2014; 264 p.
3. Ritchlin СТ, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-94
4. Schmitt J, Rosumeck S, Thomaschewski G, et al. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-anaiysis of randomized controlled trials. The British journal of dermatology 2014; 170 (2): 274-303
5. Kruglova LS, MoiseevSV Blockade of interleukin-17 — new horizons safety performance in the treatment of psoriasis. Clinical pharmacology and therapeutics 2017: 26 (2): 40-49
6. Kruglova LS, Ponich ES. The use of methotrexate and UVB 311 nm phototherapy in patients with severe psoriasis receiving biologic therapy. Kremlevsksaya medicina 2016; 4: 55-62
7. Kruglova LS, Ponich ES. Differential application of phototherapy in psoriasis. Physiotherapy, balneology and rehabilitation 2015; 6: 41-47
8. Cai Y, Fleming С, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cellular & Molecular Immunology 2012; 9 (4): 302-309
9. Raju SS. Psoriasis and lasting implications. Expert Review of Clinical Immunology 2014; 10 (21): 75-77
10. Baker BS. Recent advances in psoriasis: the role of the immune system. Imperial College Press 2000; 180 p.
11. Hannuksela-Svahn A, Pukkala E, et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000; 114: 587-590
12. Olsen JH, Frentz G, Moller H. Psoriasis and cancer. Ugeskr Laeger 1993; 155: 2687-2691
13. Pinedo-Vega JL, Castaceda-Lypez R, D6vila-Rangel Jl, Mireles-GarcHa F, RHOsMartHnez C, Lypez-Saucedo A. Skin cancer incidence in Zacatecas. Rev Med Inst Мех Seguro Soc 2014 May-Jun; 52 (3): 282-9
14. Kruglova LS, Ponich ES, Korchagkina NB. Photody-namic and systemic biological therapy of severe forms of psoriasis. Physiotherapy, balneology and rehabilitation 2015; 6: 17-20
15. Richetta AG, Mattozzi С, Salvi М, Giancristo-foro S. CD4+CD25+T-regulatory cells in psoriasis. Correlation between their numbers and biologies-induced clinical improvement. European Journal of Dermatology 2011; 21 (3): 344-348
16. Ovcina-Kurtovic N, Kasumagic-HalilovicE. Serum levels of total immuno-globulin E in patients with psoriasis: relationship with clinical type of disease. Medicinski Arhiv 2010; 64 (1): 28-29
17. Azarsiz E, Ertaml, Karaca N. IgG-anti-lgA antibodies: an autoimmune finding in patients with psoriasis vulgaris. Minerva Medica 2012; 103 (3): 183-187
18. Quatresooz P, Hermanns-Le T, Pierard GE. Usteki-numab in psoriasis immunopathology with emphasis on the TM7-IL23 axis: a primer. Journal of Biomedicine & Biotechnology 2012: 147-413
19. Kragbhalle K, Zachariae E, Zacharlae H. Methotrexate in psoriatic arthritis: A retrospective study. Acta Derm Ven 1983; 63: 165-7
20. Espinoza LR, Zakraoui L, Espinoza CG. Psoriatic arthritis: clinical response and side effects to Methotrexate therapy. J Rheum 1992; 19:872-7
21. Espinoza LR, Cuellar ML. Psoriatic arthritis: Management. In: J.H. Klippel, PA. Dieppe, eds. Rheumatology. Mosby 1998;6:23-6
22. Singh YN, Verma KK, Kumar A, Malavita AN. Methotrexate in psoriatic arthritis. JAssoc Physic India 1994; 23: 860-2
23. Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999; 140: 237-42
24. Jeffes E, McCullough J, Pittelkow M. Methotrexate therapy of psoriasis: differencial sensitivity of proliferating lym-phoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol1995; 104: 183-8
25. Vlcek F, Mikulikova D. The effect of methotrexate on activity of T-lymphocyte marcer enzymes in patients with psoriasis vulgaris. Bratisl Lek Listyl 995; 96 (3): 137-140
26. Kremer JM. Toward a better understanding of methotrexate. Arthr Rheum 2004; 50: 1370-82
27. Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory disease. Arthr Res Ther 2002; 4: 266-73
28. Cronstein BN. Low-doses methotrexate: a mainstay in the treatment of rheumatoid arthritis. PharmacologyRev 2005; 57: 163-72
29. Matherly LH, Wong SC, Angeles SM, et al. Distribution of the reduced folate carrier (RFC) versus the high affinity membrane folate binding protein (mFBP) in human tumors and tissues. ProcAm Assoc Cancer Res 1994; 35: 307-15
30. Antony AC. The biological chemistry of folate receptors. Blood 1992; 79: 2807-20
31. Nesher G, Moore TL. The in vitro effects of methotrexate on peripheral blood lymphocytes: modulation by methyl-donors and spermidine. Arthr Rheum 1990; 32: 954-9
32. Nesher G, Osborn TG, Moore TL. Effect of treatment with methotrexate, hydroxychloroquine, and prednisolon on lymphocytes polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis. Clin Exp Rheum 1997; 15:343-7
33. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-837
34. Roenigk HH, Maibach HI, Weinstein GD. Use of methotrexate in psoriasis. Arch Derm 1972; 105: 363-5
35. Carretero-Hernandez G. Metotrexatoen psoriasis: I'esnecesariaunadosis de prueba? Actas Dermosifiliogr 2012; 103: 1-4
36. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1-70
37. Paul C, Gallini A, Maza A, et al. Evidence-based recommendations on conventional systemic treatments in psoriasis: Systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2011; 25: 2-11
38. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85
39. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol2008; 158: 558-66.
| Attachment | Size |
|---|---|
| 2017_03-1_662-668.pdf | 413.39 KB |
Русский
English